SCHEMBL22018242

SCHEMBL22018242

CCOc1ncc(NC(=O)C2CC/C=C\CCCCC2)c(N2CCCCC2)c1CC

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.39
MAPK1 P28482 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
TP53 P04637 1/20 0.38
THRB P10828 1/20 0.37
MAPT P10636 2/20 0.37
GSK3B P49841 1/20 0.37
LMNA P02545 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
KDM4E B2RXH2 1/20 0.36
CYP1A2 P05177 1/20 0.36
POLB P06746 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
TSHR P16473 1/20 0.36
CYP2C19 P33261 1/20 0.36
RECQL P46063 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19059609 0.93 SMN1; SMN2 (0.43) SMN1; SMN2MAPK1MEN1KMT2ATP53
SCHEMBL22018416 0.84 MAPK1 (0.39) SMN1; SMN2MAPK1MEN1KMT2ATP53
SCHEMBL20368680 0.82 SMN1; SMN2 (0.44) SMN1; SMN2MAPK1MEN1KMT2ATP53
SCHEMBL22018233 0.81 MAPK1 (0.38) SMN1; SMN2MAPK1MEN1KMT2ATP53
SCHEMBL19059700 0.77 MAPK1 (0.42) SMN1; SMN2MAPK1MEN1KMT2ATP53
SCHEMBL18399524 0.77 MAPK1 (0.42) SMN1; SMN2MAPK1MEN1KMT2ATP53
SCHEMBL22019111 0.76 SMN1; SMN2 (0.45) SMN1; SMN2MAPK1MEN1KMT2AMAPT
SCHEMBL18399573 0.76 SMN1; SMN2 (0.45) SMN1; SMN2MAPK1MEN1KMT2AMAPT
SCHEMBL20368688 0.76 SMN1; SMN2 (0.45) SMN1; SMN2MAPK1MEN1KMT2AMAPT
SCHEMBL22018173 0.76 MAPK1 (0.37) SMN1; SMN2MAPK1MEN1KMT2ATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10828290-B2 Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors INCYTE CORPORATION (US) 2020-11-10 US disclosed
US-20200155527-A1 THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS INCYTE HOLDINGS CORPORATION 2020-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200155527-A1 THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS PIM2, PIM1, PIM3 SMN1; SMN2 3837/4885MAPK1 263/4885MEN1 3457/4885
US-10828290-B2 Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors PIM2, PIM1, PIM3 SMN1; SMN2 3837/4885MAPK1 263/4885MEN1 3457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.